<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019470</url>
  </required_header>
  <id_info>
    <org_study_id>IRPBT</org_study_id>
    <nct_id>NCT04019470</nct_id>
  </id_info>
  <brief_title>Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors</brief_title>
  <official_title>Immunomodulation Analysis on Peripheral Blood Mononuclear Cells of Radiation Therapy in Pediatric Malignant Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of radiotherapy on peripheral blood immune cell composition and
      function in pediatric malignant brain tumor patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of peripheral blood immune cells</measure>
    <time_frame>6 weeks (prior and post the radiation therapy )</time_frame>
    <description>The flow cytometric analysis of lymphocyte subtypes populations would be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activation status of T cells</measure>
    <time_frame>6 weeks (prior and post the radiation therapy )</time_frame>
    <description>Activation status of peripheral IFN-γ-producing effector CD8+ T cells by Elispot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changs of inflammatory cytokines and chemokines</measure>
    <time_frame>6 weeks (prior and post the radiation therapy )</time_frame>
    <description>Human inflammatory cytokines and chemokines will be analyzed by ELISA during radiation therapy. The cytokines and chemokines are IL-2, IL-10, IFN-γ, TNF-α</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain Tumor, Pediatric</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The brain tumors patients between the ages of 3 year and 18 years who will be received
        radiation therapy evaluated and determined by their physician
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 3 to 18

          -  To be diagnosed with malignant brain tumors

          -  To eligible for radiation therapy

          -  Karnofsky performance status ≥ 70

          -  No prior radiation exposure

          -  Informed consent signed for blood sample collection and used for research purpose

        Exclusion Criteria:

          -  Patients had received radiotherapy previously.

          -  Patients who had no histological diagnosis

          -  Patients who do not wish to participate

          -  Patients with infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital Cancer Center</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Ren MD, PhD</investigator_full_name>
    <investigator_title>Cancer Center Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

